ClinicalTrials.gg
RecruitingNCT07582835HI-TECH 2Updated May 13, 2026

Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.

A Phase 3 interventional study of Clopidogrel and Ticagrelor in Coronary Artery Disease, Percutaneous Coronary Intervention and Acute Coronary Syndromes, sponsored by Cardiocentro Ticino. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Cardiocentro Ticino · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
355
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.

Planned enrollment
16th of 78
355 · median 80
Started
2026
the only one that year
Phase 3
13 of 78
2 open now
Registered
78th of 78
by date

Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 16th largest by planned enrollment, is the only one that started in 2026, is one of 13 in phase 3, and was the 78th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing ticagrelor in Coronary Artery Disease, or all of them as a file.
02

Study summary

Patients who undergo percutaneous coronary intervention (PCI) are commonly treated with antiplatelet therapy to prevent stent thrombosis and recurrence of events. After an initial period of dual antiplatelet therapy, long-term treatment with a single P2Y12 inhibitor (such as clopidogrel, ticagrelor, or prasugrel) is often prescribed. However, the optimal drug and dose for long-term monotherapy remain uncertain, as patients may experience either insufficient platelet inhibition (leading to ischemic events) or excessive inhibition (increasing bleeding risk).

The HI-TECH 2 study aims to identify the most appropriate type and dose of P2Y12 inhibitor monotherapy to achieve a balanced level of platelet inhibition within a predefined therapeutic range. The study also seeks to better understand how blood coagulation activity evolves over time after PCI.

This is a prospective, investigator-initiated, single-center, open-label study conducted in two phases. In Phase 1, patients receive stepwise reduced doses of ticagrelor or prasugrel to determine the optimal dose that most consistently achieves the desired level of platelet inhibition. In Phase 2, patients are randomly assigned to receive clopidogrel or the optimal doses of ticagrelor or prasugrel identified in Phase 1.

The main question of the study is whether optimized ticagrelor or prasugrel regimens are more effective than standard-dose clopidogrel in achieving platelet inhibition within the target therapeutic window, as measured by validated platelet function tests. Additional objectives include evaluating the role of genetic factors in treatment response and assessing markers of coagulation activation over time.

The results of this study may help personalize long-term antiplatelet therapy after PCI, improving the balance between reducing thrombotic risk and minimizing bleeding complications.

Read the detailed description

HI-TECH 2 is a prospective, investigator-initiated, single-center, open-label clinical trial designed to optimize P2Y12 inhibitor monotherapy following percutaneous coronary intervention (PCI), with a focus on achieving a predefined therapeutic window of platelet reactivity and characterizing coagulation system activation over time.

Despite widespread use of P2Y12 inhibitor monotherapy after completion of dual antiplatelet therapy (DAPT), substantial interindividual variability in pharmacodynamic response persists. Both high platelet reactivity (HPR) and low platelet reactivity (LPR) have been associated with adverse clinical outcomes, including thrombotic and bleeding events, respectively. A therapeutic window of platelet reactivity has been proposed to balance these competing risks. However, the optimal drug selection and dosing strategy to consistently achieve this window in contemporary PCI patients remain uncertain.

The study is structured in two sequential phases.

Phase 1 (dose-finding phase):

This phase aims to identify reduced-dose regimens of ticagrelor and prasugrel that achieve platelet reactivity within the predefined therapeutic range. Patients eligible for P2Y12 inhibitor monotherapy after PCI undergo serial platelet function testing using two validated assays (VerifyNow and Multiplate) at steady state. Ticagrelor and prasugrel are administered with stepwise dose reductions at predefined intervals, allowing within-subject pharmacodynamic assessment across multiple dosing regimens. The relationship between drug dose and platelet reactivity is characterized to determine the dose associated with the highest proportion of measurements within the target therapeutic window.

Phase 2 (randomized phase):

Following identification of the optimal dosing regimens in Phase 1, patients are randomized in a 1:1:1 ratio to receive clopidogrel at standard dose or ticagrelor or prasugrel at the optimized regimens. Randomization is stratified according to key clinical variables, including clinical presentation and diabetic status. Platelet function testing is performed under standardized conditions to assess pharmacodynamic response at steady state. This phase is designed to compare the proportion of patients achieving platelet reactivity within the therapeutic window across treatment groups.

In addition to platelet function assessment, a comprehensive panel of circulating biomarkers is evaluated in a predefined subset of patients to investigate the activation and persistence of coagulation pathways following PCI. These biomarkers include markers of thrombin generation, fibrinolysis, endothelial function, and platelet activation, providing mechanistic insight into the interplay between platelet inhibition and coagulation system activity in the chronic phase after PCI.

Pharmacogenetic analyses are also incorporated to explore the influence of CYP2C19 genotype and a composite ABCD-gene score on treatment response and the likelihood of achieving the therapeutic window. This component aims to assess the potential role of genotype-guided strategies in tailoring P2Y12 inhibitor therapy.

All analyses in the randomized phase are primarily conducted according to the intention-to-treat principle, with complementary per-protocol analyses to evaluate the robustness of findings. The study is powered to detect clinically relevant differences in pharmacodynamic response between treatment strategies, with adjustment for multiple comparisons.

Overall, HI-TECH 2 integrates dose optimization, randomized comparison, biomarker profiling, and pharmacogenetics to provide a comprehensive evaluation of long-term P2Y12 inhibitor monotherapy after PCI. The results are expected to inform individualized antiplatelet strategies aimed at improving the balance between thrombotic and bleeding risk in this population.

03

Conditions studied

  • Coronary Artery Disease
  • Percutaneous Coronary Intervention
  • Acute Coronary Syndromes
  • Antiplatelet Therapy
  • Single Antiplatelet Therapy
  • Coagulation Factors

Keywords

  • Coronary Artery Disease
  • Single Antiplatelet Therapy
  • Antiplatelet therapy
  • Ticagrelor
  • Prasugrel
  • Coagulation biomarkers
  • Clopidogrel
  • Multiplate
  • VerifyNow
  • CYP2C19
  • ABCB1 gene
  • Acute Coronary Syndromes
  • Dose optimization
  • platelet function tests (PFT)
  • Percutaneous Coronary Intervention (PCI)
  • High platelet reactivity (HPR)
  • Low platelet reactivity (LPR)
  • Bleeding Risk
  • Ischemic risk
  • prothrombin fragment F1+2
  • thrombin-antithrombin (TAT) complex
  • fibrinopeptide A
  • fibrinogen
  • D-dimer
  • von Willebrand factor activity (VWF)
  • plasminogen activator inhibitor-1 (PAI-1)
  • thrombin-activatable fibrinolysis inhibitor (TAFI)
  • circulating extracellular vesicles
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Prior (≥3 months) ACS and/or PCI
  • Eligible for P2Y12 inhibitor monotherapy after an uneventful DAPT course
  • Free from ischemic (i.e. any new episode of ACS, symptomatic restenosis, stent thrombosis, stroke, any revascularization requiring prolonged DAPT) and/or bleeding events (defined as BARC ≥ 2) for at least 3 months
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Unconscious patients
  • Unable to provide written
  • Under judicial protection, tutorship or curatorship
  • Unable to understand and follow study-related instructions or unable to comply with study protocol
  • Known or allergy to clopidogrel, ticagrelor or prasugrel
  • Severe hepatic impairment
  • level \<10 g/dL or count \<100 000 cells/mL
  • Pregnant or breastfeeding women
  • less than 1 year
  • Active participation in another interventional trial
  • Need for concomitant oral anticoagulation
  • History of intracranial haemorrhage (anytime), or stroke within 3 months
  • PCI for in-stent restenosis or stent thrombosis at index PCI or within 6 months before randomization
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
355 participants (estimated)

Study arms

  • Active comparator
    Clopidogrel Monotherapy (Standard Dose) (Phase 2)

    Participants receive clopidogrel 75 mg once daily as standard-dose P2Y12 inhibitor monotherapy after completion of dual antiplatelet therapy following PCI.

    Drug: Clopidogrel

  • Experimental
    Ticagrelor Monotherapy (Optimized Dose) (Phase 2)

    Participants receive ticagrelor monotherapy at the optimized maintenance dose identified in Phase 1 of the study after discontinuation of dual antiplatelet therapy following PCI. Dose selection is based on prior dose-finding platelet function testing.

    Drug: Ticagrelor

  • Experimental
    Prasugrel Monotherapy (Optimized Dose) (Phase 2)

    Participants receive prasugrel monotherapy at the optimized maintenance dose identified in Phase 1 of the study after discontinuation of dual antiplatelet therapy following PCI. Dose selection is based on prior dose-finding platelet function testing.

    Drug: Prasugrel

Interventions

  • Clopidogrel 75 mg once daily administered as maintenance P2Y12 inhibitor monotherapy following completion of dual antiplatelet therapy after PCI. This regimen represents the standard comparator arm in the study.

    Also known as: Plavix

  • Ticagrelor monotherapy administered at the optimized maintenance dose identified in Phase 1 dose-finding stage. Dose selection is based on stepwise dose reduction with serial platelet function testing (VerifyNow P2Y12 and Multiplate) to achieve platelet reactivity within the predefined therapeutic window. Administered after completion of dual antiplatelet therapy following PCI.

    Also known as: Brilique

  • Prasugrel monotherapy administered at the optimized maintenance dose identified in Phase 1 dose-finding stage. Dose selection is based on stepwise dose reduction with serial platelet function testing (VerifyNow P2Y12 and Multiplate) to achieve platelet reactivity within the predefined therapeutic window. Administered after completion of dual antiplatelet therapy following PCI.

    Also known as: Efient

06

What researchers measure

Primary outcomes

  1. Identification of reduced doses of ticagrelor and prasugrel achieving target platelet reactivity by VerifyNow (Phase 1)

    Identification of the reduced maintenance doses of ticagrelor and prasugrel that achieve platelet reactivity within the predefined therapeutic window, defined as platelet reactivity units (PRU) \>85 and \<208, as measured by the VerifyNow P2Y12 assay. Platelet reactivity will be assessed 1 to 2 hours after intake of each dose of the P2Y12 inhibitor.

    Time frame: During the dose-finding phase (Phase 1): at baseline and at Visit 1 (at approximately 30 days), Visit 2 (at approximately 60 days), and Visit 3 (at approximately 90 days).

  2. Proportion of patients achieving platelet reactivity within the therapeutic window by VerifyNow at 3 months after randomization (Phase 2)

    Proportion of patients with platelet reactivity within the predefined therapeutic window, defined as platelet reactivity units (PRU) ≥85 and ≤208, as measured by the VerifyNow P2Y12 assay. Platelet reactivity is assessed 1 to 2 hours after witnessed intake of the maintenance dose. The primary analysis includes two comparisons: ticagrelor versus clopidogrel and prasugrel versus clopidogrel.

    Time frame: 3 months after randomization

Secondary outcomes

  1. Identification of reduced doses of ticagrelor and prasugrel achieving target platelet reactivity by Multiplate (Phase 1)

    Identification of the reduced maintenance doses of ticagrelor and prasugrel that achieve platelet reactivity within the predefined therapeutic window, defined as area under the curve (AUC) ≥18 and ≤46, as measured by the Multiplate analyzer. Platelet reactivity will be assessed 1 to 2 hours after intake of each dose of the P2Y12 inhibitor.

    Time frame: During the dose-finding phase (Phase 1): at baseline and at Visit 1 (at approximately 30 days), Visit 2 (at approximately 30 days), and Visit 3 (at approximately 30 days).

  2. Proportion of patients achieving platelet reactivity within the therapeutic window by Multiplate at 3 months after randomization (Phase 2)

    Proportion of patients with platelet reactivity within the predefined therapeutic window, defined as area under the curve (AUC) ≥18 and ≤46, as measured by the Multiplate analyzer. Platelet reactivity is assessed 1 to 2 hours after witnessed intake of the maintenance dose.

    Time frame: 3 months after randomization (Phase 2)

  3. Platelet reactivity within the therapeutic window after loading dose and at 6 months after randomization (Phase 2)

    Proportion of patients achieving platelet reactivity within the predefined therapeutic window (PRU 85-208 by VerifyNow and/or AUC 18-46 by Multiplate) at baseline, at 3 to 6 hours after administration of the loading dose of the randomized P2Y12 inhibitor, and at 6 months follow-up, 1 to 2 hours after witnessed intake of the maintenance dose.

    Time frame: At randomization and 6 months after randomization (Phase 2)

  4. Proportion of patients with high and low platelet reactivity (Phase 2)

    Proportion of patients with high platelet reactivity (HPR: PRU ≥208 or AUC ≥46) and low platelet reactivity (LPR: PRU ≤85 or AUC ≤18), as assessed by the VerifyNow P2Y12 assay and Multiplate analyzer. Measurements will be performed 3 to 6 hours after the loading dose following randomization, and 1 to 2 hours after intake of the maintenance dose at approximately 3 months and 6 months.

    Time frame: At baseline, 3 to 6 hours after the loading dose following randomization, and 1 to 2 hours after intake of the maintenance dose at approximately 3 months and 6 months. (Phase 2)

  5. Major adverse cardiovascular events (MACE) (Phase 2)

    Composite of death, myocardial infarction, or stroke, and individual components.

    Time frame: Up to 6 months after randomization (Phase 2)

  6. BARC bleeding events (Phase 2)

    Bleeding events classified according to the Bleeding Academic Research Consortium (BARC) criteria. The BARC scale ranges from 0 to 5, where 0 indicates no bleeding and 5 indicates fatal bleeding; higher scores correspond to worse outcomes.

    Time frame: Up to 6 months after randomization (Phase 2)

  7. Drug adherence (Phase 2)

    Assessment of treatment adherence measured as the proportion of prescribed doses taken over the study period, expressed as a percentage (0% to 100%), where higher percentages indicate better adherence. Adherence will be evaluated using patient self-report (e.g., medication diary) and, where available, electronic adherence monitoring systems (e.g., automatic pill counting devices).

    Time frame: Up to 6 months after randomization (Phase 2)

  8. Drug tolerability (Phase 2)

    Assessment of drug tolerability based on the incidence, type, and severity of adverse events and treatment discontinuations, as documented in the annual safety report. Adverse events will be summarized descriptively; higher incidence and greater severity indicate worse tolerability.

    Time frame: Up to 6 months after randomization (Phase 2)

  9. Correlation between genotype status and platelet reactivity measured by VerifyNow P2Y12 assay (Phase 2)

    Assessment of the correlation between genotype status-including variants of CYP2C19 and ABCB1, determined by genotyping assay-and platelet reactivity measured by the VerifyNow P2Y12 assay, expressed in P2Y12 Reaction Units (PRU). Correlation will be quantified using an appropriate correlation coefficient (e.g., Pearson or Spearman), ranging from -1 to +1, where values closer to ±1 indicate stronger relationships.

    Time frame: Up to 6 months after randomization (Phase 2)

  10. Change in cardiac troponin levels (Phase 2)

    Change from baseline in cardiac troponin concentration, measured in ng/L using a validated immunoassay. Higher values indicate greater cardiac injury.

    Time frame: From baseline to 6 months after randomization

  11. Change in prothrombin fragment 1+2 levels (Phase 2)

    Change from baseline in prothrombin fragment 1+2 concentration, measured in pmol/L using a validated assay. Higher values indicate increased thrombin generation.

    Time frame: From baseline to 6 months after randomization

  12. Change in thrombin-antithrombin (TAT) complex levels (Phase 2)

    Change from baseline in thrombin-antithrombin complex concentration, measured in µg/L. Higher values indicate increased coagulation activation.

    Time frame: From baseline to 6 months after randomization

  13. Change in fibrinopeptide A levels (Phase 2)

    Change from baseline in fibrinopeptide A concentration, measured in ng/mL. Higher values indicate increased fibrin formation.

    Time frame: From baseline to 6 months after randomization

  14. Change in fibrinogen levels (Phase 2)

    Change from baseline in fibrinogen concentration, measured in g/L. Higher values indicate increased coagulation potential.

    Time frame: From baseline to 6 months after randomization

  15. Change in fibrin monomer levels (Phase 2)

    Change from baseline in fibrin monomer concentration, measured in µg/mL. Higher values indicate increased fibrin formation.

    Time frame: From baseline to 6 months after randomization

  16. Change in D-dimer levels (Phase 2)

    Change from baseline in D-dimer concentration, measured in mg/L FEU. Higher values indicate increased fibrinolysis and clot turnover.

    Time frame: From baseline to 6 months after randomization

  17. Change in von Willebrand factor activity (Phase 2)

    Change from baseline in von Willebrand factor activity, expressed as a percentage (%). Higher values indicate increased platelet adhesion activity.

    Time frame: From baseline to 6 months after randomization

  18. Change in plasminogen activator inhibitor-1 (PAI-1) levels (Phase 2)

    Change from baseline in PAI-1 concentration, measured in ng/mL. Higher values indicate reduced fibrinolysis.

    Time frame: From baseline to 6 months after randomization

  19. Change in thrombin-activatable fibrinolysis inhibitor (TAFI) levels (Phase 2)

    Change from baseline in TAFI concentration, measured in µg/mL. Higher values indicate reduced fibrinolysis.

    Time frame: From baseline to 6 months after randomization

  20. Change in circulating extracellular vesicle levels (Phase 2)

    Change from baseline in circulating extracellular vesicle concentration, measured as particles/µL using a validated analytical method. Higher values may reflect increased cellular activation or injury.

    Time frame: From baseline to 6 months after randomization

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Apr 2028, 24 months later.

Of 62 phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 58. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
May 13, 2026
StartEst.
Apr 20, 2026
Primary completionEst.
Apr 2028
CompletionEst.
Apr 2028
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07582835
Lead sponsor
Cardiocentro Ticino
Responsible party
Marco Valgimigli (Cardiology Chief Prof. Dr. Med, Cardiocentro Ticino) — Principal investigator
First posted
May 13, 2026
Start date
Apr 20, 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Apr 2028 (estimated)
Last update
May 13, 2026

Study contacts

Marco Valgimigli, Cardiology Chief Prof. Dr. Med
Contact
marco.valgimigli@eoc.ch
+41 (0) 91 811 51 11
Enrico Frigoli, Dr. Med
Contact
enrico.frigoli@eoc.ch
+41 (0)91 811 53 04
Marco Valgimigli, Cardiology Chief Prof. Dr. Med
principal investigator · Cardiocentro Ticino

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ticagrelor · Prasugrel

Start the discussion